1. The risks of therapeutic genome editing

    Interviewee/Contributer: Houria Bachtarzi and Tim Farries

    Organisation: ERA Consulting (UK) Ltd

    Read more

  2. European biotech searches for growth capital

    Interviewee/Contributer: Eric Castaldi

    Organisation: Argenx NV

    Read more

  3. Janssen Oncology: When the data show durable response

    Interviewee/Contributer: Catherine Taylor

    Organisation: Janssen Oncology

    Read more

  4. Real-world evidence - the new healthcare currency

    Interviewee/Contributer: Tara Raveendran

    Organisation: Shore Capital

    Read more

  5. Case study - the merits of adaptive trial design

    Interviewee/Contributer: Erik van den Berg

    Organisation: AM-Pharma BV

    Read more

  6. The next step for EU health technology assessment

    Interviewee/Contributer: Jane Morrison

    Organisation: MedNous

    Read more

  7. When is one drug more effective than another?

    Interviewee/Contributer: Alex Gee

    Organisation: ICON P&MA

    Read more

  8. Ipsen aspires to role as speciality oncology player

    Interviewee/Contributer: Robin Davison

    Organisation: New Science Global Healthcare Fund

    Read more

  9. How Pharma is targeting checkpoint inhibitors

    Interviewee/Contributer: Bruno Pagliara

    Organisation: 

    Read more

  10. Progress towards personalised cancer vaccines

    Interviewee/Contributer: Cornelis Melief

    Organisation: ISA Pharmaceuticals BV

    Read more